ATE437872T1 - Proteinkinaseinhibitoren - Google Patents
ProteinkinaseinhibitorenInfo
- Publication number
- ATE437872T1 ATE437872T1 AT04795080T AT04795080T ATE437872T1 AT E437872 T1 ATE437872 T1 AT E437872T1 AT 04795080 T AT04795080 T AT 04795080T AT 04795080 T AT04795080 T AT 04795080T AT E437872 T1 ATE437872 T1 AT E437872T1
- Authority
- AT
- Austria
- Prior art keywords
- protein kinase
- kinase inhibitors
- disclosed
- cycl1
- cycl2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51148603P | 2003-10-14 | 2003-10-14 | |
US51148903P | 2003-10-14 | 2003-10-14 | |
US60852904P | 2004-09-09 | 2004-09-09 | |
PCT/US2004/033870 WO2005037825A2 (en) | 2003-10-14 | 2004-10-14 | Protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE437872T1 true ATE437872T1 (de) | 2009-08-15 |
Family
ID=34468370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04795080T ATE437872T1 (de) | 2003-10-14 | 2004-10-14 | Proteinkinaseinhibitoren |
Country Status (14)
Country | Link |
---|---|
US (4) | US7326712B2 (de) |
EP (1) | EP1678166B1 (de) |
JP (1) | JP4845736B2 (de) |
AT (1) | ATE437872T1 (de) |
AU (1) | AU2004282179B2 (de) |
CA (1) | CA2542076C (de) |
CY (1) | CY1110504T1 (de) |
DE (1) | DE602004022318D1 (de) |
DK (1) | DK1678166T3 (de) |
ES (1) | ES2344007T3 (de) |
PL (1) | PL1678166T3 (de) |
PT (1) | PT1678166E (de) |
SI (1) | SI1678166T1 (de) |
WO (1) | WO2005037825A2 (de) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
CA2531327A1 (en) * | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | Compounds and therapeutical use thereof |
WO2006074147A2 (en) * | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
US20090099165A1 (en) * | 2003-10-14 | 2009-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
US20090143399A1 (en) * | 2003-10-14 | 2009-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
US20080051414A1 (en) * | 2003-10-14 | 2008-02-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
US20070244114A1 (en) * | 2004-07-06 | 2007-10-18 | Myriad Genetics, Incorporated | Compounds and therapeutical use thereof |
WO2006044687A2 (en) | 2004-10-15 | 2006-04-27 | Takeda San Diego, Inc. | Kinase inhibitors |
EP1776982A1 (de) * | 2005-10-18 | 2007-04-25 | Argenta Discovery Limited | Pyrimidine Derivate als Modulator der Histamine Rezeptor |
US20080269239A1 (en) * | 2004-11-11 | 2008-10-30 | Argenta Discovery Ltd. | Pyrimidine Compounds as Histamine Modulators |
US8258145B2 (en) * | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
BRPI0609956A2 (pt) * | 2005-04-28 | 2010-05-18 | Supergen Inc | inibidores de proteìna quinase |
US20070004763A1 (en) * | 2005-06-10 | 2007-01-04 | Nand Baindur | Aminoquinoline and aminoquinazoline kinase modulators |
US7825244B2 (en) * | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
US20060281771A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
US20070004660A1 (en) * | 2005-06-10 | 2007-01-04 | Baumann Christian A | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines |
US20070249640A1 (en) * | 2005-06-16 | 2007-10-25 | Myriad Genetics, Incorporated | Pharmaceutical compositions and use thereof |
EP1767537A1 (de) * | 2005-09-21 | 2007-03-28 | Cellzome (UK) Ltd. | Pyrimidinverbindungen für die Behandlung entzündlicher Erkrankungen |
US20070149506A1 (en) | 2005-09-22 | 2007-06-28 | Arvanitis Argyrios G | Azepine inhibitors of Janus kinases |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
AU2006331656B2 (en) * | 2005-12-22 | 2012-08-09 | Icagen, Inc. | Calcium channel antagonists |
EP1829879A1 (de) * | 2006-02-10 | 2007-09-05 | Cellzome (UK) Ltd. | Amino Pyrimidine Verbindungen zur Behandlung von entzündlichen Erkrankungen |
EP2076266A2 (de) * | 2006-05-31 | 2009-07-08 | The Board of Trustees of the Leland Stanford Junior University | Verfahren zur behandlung von entzündlichen erkrankungen mit tyroskin-kinase-hemmern |
FR2903387B1 (fr) * | 2006-07-05 | 2008-08-29 | Alcatel Sa | Actionneur pour systemes de guidage d'equipements spatiaux a taux de rotation variable |
US8735411B2 (en) | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
US7985745B2 (en) | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008055233A1 (en) * | 2006-10-31 | 2008-05-08 | Supergen, Inc. | Protein kinase inhibitors |
ES2415863T3 (es) | 2006-12-22 | 2013-07-29 | Incyte Corporation | Heterociclos sustituidos como inhibidores de Janus Quinasas |
US7820684B2 (en) | 2007-03-01 | 2010-10-26 | Supergen, Inc. | Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same |
EP2139869A2 (de) * | 2007-04-13 | 2010-01-06 | SuperGen, Inc. | Axl-kinasehemmer |
WO2009004329A1 (en) * | 2007-07-02 | 2009-01-08 | Cancer Research Technology Limited | 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors |
WO2009023876A1 (en) * | 2007-08-16 | 2009-02-19 | Myriad Genetics, Inc. | Method of treating non-small cell lung cancer |
US7960400B2 (en) | 2007-08-27 | 2011-06-14 | Duquesne University Of The Holy Ghost | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof |
US7982035B2 (en) | 2007-08-27 | 2011-07-19 | Duquesne University Of The Holy Spirit | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof |
EP2217716A4 (de) * | 2007-11-09 | 2011-02-09 | Salk Inst For Biological Studi | Verwendung von tam-rezeptor-inhibitoren als antimikrobielle mittel |
WO2009081222A1 (en) * | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
JP5575110B2 (ja) * | 2008-04-21 | 2014-08-20 | レクシコン ファーマシューティカルズ インコーポレイテッド | Limk2阻害剤、それらを含む組成物、及びそれらの使用の方法 |
CN102014627B (zh) * | 2008-04-30 | 2014-10-29 | 国家卫生研究院 | 作为极光激酶抑制剂的稠合双环嘧啶化合物 |
US20100016247A1 (en) * | 2008-07-21 | 2010-01-21 | Florida State University Research Foundation | Using budding yeast to screen for inhibitors of aurora kinases |
KR101718386B1 (ko) * | 2008-09-26 | 2017-03-21 | 내셔날 헬스 리서치 인스티튜트 | 단백질 키나아제 억제제로서의 융합 다환 화합물 |
JP5785940B2 (ja) | 2009-06-09 | 2015-09-30 | アブラクシス バイオサイエンス, エルエルシー | トリアジン誘導体類及びそれらの治療応用 |
US8877924B2 (en) | 2009-06-09 | 2014-11-04 | NantBio Inc. | Benzyl substituted triazine derivatives and their therapeutical applications |
EP2440048B8 (de) | 2009-06-09 | 2015-12-16 | NantBioScience, Inc. | Isochinolin-, chinolin- und chinazolinderivate als hemmer der hedgehog-signalisierung |
JP5699149B2 (ja) | 2009-09-04 | 2015-04-08 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Bruton型チロシンキナーゼ阻害薬 |
WO2011056739A1 (en) * | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Compounds and methods |
WO2011150198A1 (en) | 2010-05-27 | 2011-12-01 | Ambit Biosciences Corporation | Azolyl urea compounds and methods of use thereof |
CN101857588B (zh) * | 2010-06-08 | 2013-11-27 | 东南大学 | 4-芳香胺基喹唑啉类衍生物及其用途 |
TWI527818B (zh) | 2011-03-15 | 2016-04-01 | 特留斯治療學有限公司 | 三環旋轉酶抑制劑 |
EP2755939A4 (de) | 2011-07-14 | 2015-04-15 | Keith R Latham | Halogenierte phenole für diagnose, antioxidantienschutz und arzneimittelabgabe |
HUE052198T2 (hu) | 2011-07-21 | 2021-04-28 | Sumitomo Dainippon Pharma Oncology Inc | Heterociklusos protein kináz inhibitorok |
BR112014010938A2 (pt) | 2011-11-09 | 2017-05-16 | Cancer Res Tech Ltd | compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico |
SG11201404241SA (en) | 2012-01-27 | 2014-08-28 | Univ Montreal | Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells |
WO2013115167A1 (ja) * | 2012-01-31 | 2013-08-08 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アムバチニブ誘導体 |
EP2855448B1 (de) | 2012-05-15 | 2017-02-08 | Cancer Research Technology Ltd | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluormethyl)-2-pyridyl]amino]pyrazin-2-carbonitril und therapeutische verwendungen davon |
CN102690274A (zh) * | 2012-05-24 | 2012-09-26 | 盛世泰科生物医药技术(苏州)有限公司 | 4-氯-2-甲基嘧啶苯并呋喃合成工艺 |
AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
EP2895488A1 (de) | 2012-09-12 | 2015-07-22 | Trius Therapeutics, Inc. | Tricyclische gyrase-inhibitoren zur verwendung als antibakterielle wirkstoffe |
CN102875558A (zh) * | 2012-11-05 | 2013-01-16 | 贵州大学 | 2-氯-4-取代-8-硝基苯并呋喃[3,2-d]嘧啶类化合物及其制备方法和用途 |
CN104045642B (zh) * | 2013-03-14 | 2016-08-24 | 上海医药工业研究院 | 含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用 |
CN109616572B (zh) * | 2013-03-26 | 2023-01-17 | 株式会社半导体能源研究所 | 发光装置 |
CN105899511B (zh) * | 2013-09-11 | 2019-06-07 | 默沙东公司 | 三环促旋酶抑制剂 |
CA2952568C (en) | 2014-01-31 | 2018-07-10 | Goldcorp Inc. | Process for separation of at least one metal sulfide from a mixed sulfide ore or concentrate |
KR102278306B1 (ko) | 2015-06-05 | 2021-07-15 | 헤마-퀘벡 | 조혈 줄기세포를 전구 세포로 배양 및/또는 분화시키는 방법 및 그의 용도 |
WO2017109637A1 (en) | 2015-12-25 | 2017-06-29 | Semiconductor Energy Laboratory Co., Ltd. | Compound, light-emitting element, display device, electronic device, and lighting device |
CN105461728A (zh) * | 2015-12-29 | 2016-04-06 | 中山大学 | 一种4-取代胺基-6-甲氧羰基苯并呋喃并[2,3-d]嘧啶类化合物及制备方法 |
DK3474846T3 (da) * | 2016-06-22 | 2023-02-06 | Univ Vanderbilt | Positive, allosteriske modulatorer af den muskarinske acetylcholinreceptor m4 |
RU2019104758A (ru) | 2016-07-21 | 2020-08-21 | Байоджен Ма Инк. | Сукцинатные формы и композиции ингибиторов тирозинкиназы брутона |
MA46722A (fr) | 2016-11-07 | 2019-09-11 | Univ Vanderbilt | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 |
EP3558309B1 (de) | 2016-11-07 | 2023-07-26 | Vanderbilt University | Positive allosterische modulatoren des muskarinischen acetylcholinrezeptors m4 |
US10927126B2 (en) | 2016-11-07 | 2021-02-23 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
TW201930311A (zh) | 2017-12-05 | 2019-08-01 | 泛德比爾特大學 | 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑 |
JP2021505581A (ja) | 2017-12-05 | 2021-02-18 | ヴァンダービルト ユニヴァーシティ | ムスカリン性アセチルコリンレセプターm4のポジティブアロステリック調節因子 |
BR112020020246A8 (pt) | 2018-04-05 | 2022-10-18 | Sumitomo Dainippon Pharma Oncology Inc | Inibidores de cinase axl e uso dos mesmos |
JP2022520361A (ja) | 2019-02-12 | 2022-03-30 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 複素環式タンパク質キナーゼ阻害剤を含む製剤 |
CN112300082B (zh) * | 2019-07-26 | 2022-04-26 | 暨南大学 | 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06220059A (ja) * | 1993-01-28 | 1994-08-09 | Tanabe Seiyaku Co Ltd | 縮合ピリミジン誘導体及びその製法 |
US5679683A (en) * | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB9508535D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
WO1997017329A1 (fr) * | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant |
CN1169795C (zh) * | 1996-10-01 | 2004-10-06 | 协和发酵工业株式会社 | 环胺取代的含氮杂环化合物及其组合物 |
EP0837063A1 (de) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazolinderivate |
JPH10175977A (ja) * | 1996-12-13 | 1998-06-30 | Takeda Chem Ind Ltd | 縮合インドール誘導体、その製造法及び用途 |
ATE294796T1 (de) | 1998-10-08 | 2005-05-15 | Astrazeneca Ab | Chinazolin derivate |
CA2384291A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
CZ20021010A3 (cs) | 1999-09-21 | 2002-06-12 | Astrazeneca Ab | Nové sloučeniny chinazolinu a farmaceutické kompozice, které je obsahují |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
PL360439A1 (en) * | 2000-06-28 | 2004-09-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
JP2003183283A (ja) * | 2001-12-18 | 2003-07-03 | Takeda Chem Ind Ltd | 縮合インドール化合物、その製造法および用途 |
AU2002353196B2 (en) | 2001-12-24 | 2008-01-17 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
GB0313766D0 (en) * | 2003-06-13 | 2003-07-23 | Xenova Ltd | Pharmaceutical compounds |
-
2004
- 2004-10-14 DE DE602004022318T patent/DE602004022318D1/de active Active
- 2004-10-14 US US10/965,313 patent/US7326712B2/en not_active Expired - Fee Related
- 2004-10-14 ES ES04795080T patent/ES2344007T3/es active Active
- 2004-10-14 DK DK04795080T patent/DK1678166T3/da active
- 2004-10-14 EP EP04795080A patent/EP1678166B1/de not_active Not-in-force
- 2004-10-14 PL PL04795080T patent/PL1678166T3/pl unknown
- 2004-10-14 AU AU2004282179A patent/AU2004282179B2/en not_active Ceased
- 2004-10-14 JP JP2006535644A patent/JP4845736B2/ja not_active Expired - Fee Related
- 2004-10-14 AT AT04795080T patent/ATE437872T1/de active
- 2004-10-14 CA CA2542076A patent/CA2542076C/en not_active Expired - Fee Related
- 2004-10-14 SI SI200431206T patent/SI1678166T1/sl unknown
- 2004-10-14 WO PCT/US2004/033870 patent/WO2005037825A2/en active Application Filing
- 2004-10-14 PT PT04795080T patent/PT1678166E/pt unknown
-
2005
- 2005-03-29 US US11/092,863 patent/US7335662B2/en not_active Expired - Fee Related
- 2005-03-29 US US11/092,809 patent/US7326713B2/en not_active Expired - Fee Related
- 2005-03-29 US US11/092,168 patent/US7312226B2/en not_active Expired - Fee Related
-
2009
- 2009-10-13 CY CY20091101047T patent/CY1110504T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US7326713B2 (en) | 2008-02-05 |
EP1678166B1 (de) | 2009-07-29 |
WO2005037825A3 (en) | 2006-03-30 |
EP1678166A2 (de) | 2006-07-12 |
CY1110504T1 (el) | 2015-04-29 |
US20050239794A1 (en) | 2005-10-27 |
AU2004282179B2 (en) | 2011-05-19 |
CA2542076A1 (en) | 2005-04-28 |
US20050239793A1 (en) | 2005-10-27 |
WO2005037825A2 (en) | 2005-04-28 |
US7335662B2 (en) | 2008-02-26 |
CA2542076C (en) | 2013-02-26 |
SI1678166T1 (sl) | 2009-10-31 |
PL1678166T3 (pl) | 2009-12-31 |
DK1678166T3 (da) | 2009-11-09 |
ES2344007T3 (es) | 2010-08-16 |
US7326712B2 (en) | 2008-02-05 |
PT1678166E (pt) | 2009-10-30 |
JP4845736B2 (ja) | 2011-12-28 |
JP2007510627A (ja) | 2007-04-26 |
AU2004282179A1 (en) | 2005-04-28 |
DE602004022318D1 (de) | 2009-09-10 |
US20050227992A1 (en) | 2005-10-13 |
US20050277658A1 (en) | 2005-12-15 |
US7312226B2 (en) | 2007-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE437872T1 (de) | Proteinkinaseinhibitoren | |
MX2007013624A (es) | Inhibidores de proteina cinasa. | |
DE602004007239D1 (de) | 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN | |
GB0112348D0 (en) | Compounds | |
EA200600973A1 (ru) | ПИРИДО[2,3-d] ПИРИМИДИН-2,4-ДИАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE 2 | |
SG149033A1 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
ATE371656T1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
MY138352A (en) | Benzothiazole derivatives | |
MXPA05010958A (es) | Derivados indazol como inhibidores jnk. | |
MY141220A (en) | Pyrazole derivatives as inhibitors of receptor tyrosine kinases | |
EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
MX2010001020A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas. | |
SE0202429D0 (sv) | Novel Compounds | |
DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
AU2003250471A8 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
WO2006124996A3 (en) | Inhibitors of polo-like kinase-1 | |
HK1081194A1 (en) | 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof | |
MY133527A (en) | Isoquinoline derivatives | |
DE602007001463D1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
DE602004015277D1 (de) | Substituierte-1-phthalazinamine als vr-1-antagonisten | |
ATE308540T1 (de) | Antithrombosemittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1678166 Country of ref document: EP |